Lineage Cell Therapeutics Inc. — Director's Dealing 2021

May 9, 2021

ORM F 4
---------------

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
Jayasuriya Anula	Lineage Cell Therapeutics, Inc. [ LCTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X Director _____ 10% Owner
		_ Officer (give title below) ___ Other (specify below)
C/O LINEAGE CELL	5/4/2021
THERAPEUTICS, INC., 2173 SALK
AVENUE, SUITE 200
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
CARLSBAD, CA 92008 (City) (State) (Zip)		_X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Trans. Date 2A. Deemed 3. Trans. Code 4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned 6. 7. Nature (Instr. 3) Execution (Instr. 8) or Disposed of (D) Following Reported Transaction(s) Ownership of Indirect Date, if any (Instr. 3, 4 and 5) (Instr. 3 and 4) Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (A) or (I) (Instr. Code V Amount (D) Price 4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Stock Option (Right to Buy)	\$2.58	5/4/2021		A		90000		(1)	5/3/2031	Common Shares	90000	\$0.00	90000	D

Explanation of Responses:

(1) This option vests in 36 monthly installments beginning on the one-month anniversary of the date of grant, subject to the reporting person's continuous service on the board of directors of the issuer.

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% OwnerOfficerOther
Jayasuriya Anula C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200 CARLSBAD, CA 92008	X

Signatures

/s/ Daniel W. Collins, as Attorney-in-Fact 5/6/2021

\\Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.